Skip to main content

Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome: from molecular genetics to clinical features


Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome is a rare but fatal autosomal recessive multisystem disorder caused by mutations in the VPS33B or VIPAR gene. The classical presentation of ARC includes congenital joint contractures, renal tubular dysfunction, and cholestasis. Additional features include ichthyosis, central nervous system malformation, platelet anomalies, and severe failure to thrive. Diagnosis of ARC syndrome relies on clinical features, organ biopsy, and mutational analysis. However, no specific treatment currently exists for this syndrome.


This is an overview of the latest knowledge regarding the genetic features and clinical manifestations of ARC syndrome. Greater awareness and understanding of this syndrome should allow more timely intervention with potential for improving long-term outcome.

"What is known - what is new" (Authors' summary)

Arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome (MIM 208085), caused by mutations in the VPS33B or VIPAR gene, is a rare autosomal recessive multisystem disorder involving the liver, kidney, skin, and central nervous and musculoskeletal systems. In general, case reports of patients with ARC syndrome are not uncommon in Saudi Arabia and Pakistan, along with several sporadic cases all around the world. To help clinicians raise awareness of general clinical picture of ARC syndrome, we comprehensively characterize its major clinical presentation, namely, arthrogryposis, renal dysfunction, cholestasis, and other associated features.

Though a Leiden Open-Source Variation Database (LOVD) for ARC has been established by collating all relevant published variants observed in VPS33B and VIPAR, further analysis is still in urgent need to highlight variants that have been classified as "pathogenic" worldwide, and ultimately facilitate accurately counseling and improved disease management. Thus, we compile a total of 49 pathogenic VPS33B mutations and 14 pathogenic VIPAR mutations listed in the ARC-LOVD database to date.

All in all, this article focuses on the latest knowledge regarding both clinical and genetic features of ARC syndrome and discusses appropriate diagnosis and available treatment option currently, which gives clinicians an insight in children at risk of dying from this severe disease. Moreover, it still stands in need of future attempts at gene therapy for improvements in managing or even curing ARC syndrome.


Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome (MIM 208085) is a rare autosomal recessive disorder, which was first recognized in the offspring of a consanguineous marriage in 1973 [1]. As a fatal multisystem disorder, an affected child would present a series of clinical features in musculoskeletal systems, kidney, liver, and central nervous at birth. The characteristic features of ARC syndrome include arthrogryposis, renal tubular acidosis, and neonatal cholestatic jaundice (see Figure 1) [2]. These features are sometimes accompanied by additional presentations, including ichthyosis (~50%), platelet anomalies (~25%), agenesis of the corpus callosum (>20%), congenital cardiovascular anomalies (~10%), deafness, recurrent infection, and internal bleeding owing to coagulation dysfunction (see Table 1). The laboratory investigations and biopsy findings of liver or kidney could contribute to further evaluation and confirmation of ARC syndrome. Still, it may be very likely that mild or atypical symptoms at birth and during the first few weeks would lead to ignorance, misdiagnose and delayed treatment of this life-threating disorder. Consequently, the prognosis of ARC syndrome is so poor that the majority of patients fail to survive beyond the first year of life [3],[4].

Figure 1
figure 1

An infant with ARC syndrome showing arthrogryposis and ichthyotic skin. (Reproduction permission of John Wiley and Sons License, Number: 3438240519407).

Table 1 Clinical characteristics of patients with ARC syndrome

The locus of this disorder has been mapped to chromosome 5q26.1, and germline mutations have been identified in vacuolar protein sorting 33 homolog B (VPS33B; MIM 608552) and VPS33B-interacting protein, apical–basolateral polarity regulator (VIPAR; MIM 613401) [3],[5],[6]. VPS33B encodes a 617-amino-acid protein that is a homolog of yeast Vps33p, a class C vacuolar protein sorting (vps) protein. Vps33p, along with other class C vps proteins, comprise the two multiprotein complexes, homotypic protein sorting (HOPS) and class C core vacuole/endosome tethering (CORVET), to play an essential role in intracellular vesicular trafficking pathways [7]. VPS33B is a member of the Sec1/Munc18 family proteins, which interact with soluble NSF attachment protein receptors (SNAREs). SNAREs are involved in a variety of processes—including vesicular exocytosis, synaptic transmission, and general secretion—by facilitating vesicle targeting and fusion [8]. Once mutations develop in the human VPS33B gene, the interaction between the expressed mutant protein and the SNARE protein at the late endosomal stage may be impeded and lead to abnormal localization or accumulation of plasma proteins in polarized cells, providing partial insights into the nature of the molecular pathophysiology of ARC syndrome.

VPS33B mutations are detectable in approximately 75% of patients with a clinical diagnosis of ARC syndrome [9]. Apart from locus heterogeneity or failure to detect mutation by direct sequencing analysis, another causative gene of the ARC syndrome, VIPAR (also called C14ORF133), was subsequently identified by combining functional and genetic approaches [6]. VIPAR consists of a golgin A5 domain and shares significant homology with the C-terminal region of Vps16, which exhibits pleiotropic effects in polarity and apical membrane protein restriction through the formation of VPS33B-VIPAR complexes [10]. The role of VPS33B-VIPAR complexes are suggested to involve the RAB11A-dependent apical recycling pathway and transcriptional regulation of adherent proteins such as E-cadherin, which ensures normal cellular structure with apical basolateral polarity [6]. It is noteworthy that further research has confirmed the role of epidermal growth factor (EGF) stimulation in the interactions between SPE-39—the Caenorhabditis elegans ortholog of VIPAR—and Vps33B by tyrosine phosphorylation and ubiquitination of SPE-39 [11]-[13]. Alternatively, the apical membrane protein was observed to be misrecruited to basolateral membranes and into the late endosomes and lysosomes in knockdown/knockout studies of VPS33B or VIPAR[14]. Subsequently, abnormal organelle biogenesis may hinder the generation and maintenance of tissue structures, such as bile ducts and renal tubules, ultimately resulting in cholestasis and abnormal urine. These proteins are found at various locations throughout the body, including the skeletal muscles, kidneys, liver, skin, heart, lungs, and brain, which explains the multisystemic symptoms that are characteristic of the ARC clinical phenotype [5],[6],[15].

Clinical presentation of ARC syndrome


Arthrogryposis is a primary symptom of ARC syndrome and presents with a spectrum of manifestations, including muscle atrophy, radial deviation of the wrist, dislocation of both hip joints, flexion contracture of the knee joints, and calcaneovalgus [2]. Musculoskeletal abnormalities observed during the first few weeks of life are not generally evident—or perhaps they are simply absent or atypical in certain instances of VPS33B mutations, such as 971delA/K324fs [16],[17]. The pathogenesis characteristic of ARC syndrome is primarily degeneration of anterior motor neurons, whereas the severity of arthrogryposis may be traced to placental insufficiency during pregnancy with oligohydramnios in the mother and growth restriction of the fetus. In addition, osteopenia and pathological fractures in ARC syndrome are related to impaired reabsorption linked to renal tubular and secondary hyperparathyroidism. Nevertheless, fractures and osteopenia are due to decreased or absent fetal movements in other kind of congenital arthrogryposis such as Bruck syndrome [18]. In case of osteopenia and fractures with arthrogryposis at birth, it is also suggested that ARC syndrome should be included in the differential diagnosis. Especial attention should be paid to the patients associated with other clinical features, such as renal tubular dysfunction, and cholestasis.

Renal tubular dysfunction

Renal tubular dysfunction manifests in the form of Fanconi syndrome, with symptoms including renal tubular acidosis, nephrogenic diabetes insipidus, glucosuria, aminoaciduria, and phosphaturia [19],[20]. During episodes of intercurrent illness, renal tubular acidosis may be notably exacerbated, which is symptomatic of renal tubular calcification and degeneration. Renal ultrasonography may be suggestive of nephrocalcinosis or a small dysplastic kidney, accompanied by inflammatory reaction of the renal interstitium and focus, sclerosis of some glomeruli, and tubular distortion and degeneration, per the results of renal biopsy [3],[16].

Neonatal cholestatic jaundice

The third primary feature of ARC syndrome is neonatal cholestatic jaundice, concurrent with hepatomegaly, which is the most common characteristic of ARC syndrome. The presentation of neonatal cholestatic jaundice in ARC syndrome is distinct from the other clinical presentations of neonatal cholestatic jaundice; patients who have ARC syndrome and develop neonatal cholestatic jaundice typically present with no biliary obstruction, have consistently low γ-glutamyl transpeptidase (γGT) levels, and have normal or slightly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, although they have jaundice and liver cell dysfunction [17]. Indeed, it is well accepted that low GGT cholestasis is a differential feature of ARC syndrome. It is even recommended that patients with low-GGT conjugated hyperbilirubinemia associated with ichthyosis, deafness, platelet dysfunction and central nervous system malformation should be related to VPS33B disease [17].Furthermore, liver biopsies suggest signs of paucity of bile ducts, giant cell transformation, bile plug or lipofuscin deposition, and portal fibrosis in these cases, which could exclude biliary atresia specifically [3],[21],[22].

Other associated features of ARC syndrome

Additional clinical symptoms of ARC syndrome principally include ichthyosis, abnormal platelet count and function, secondary infection, and cardiovascular anomalies [3],[9]. Most patients are affected with ichthyosis (a heterogeneous family of skin disorders) stemming from defects in the SNARE protein, which participates in secretion and function in epidermal cohesion and waterproofing of lamellar granules [23],[24]. Despite the fact that abnormal lamellar granule secretion exist in both ARC syndrome and cerebral dysgenesis–neuropathy–ichthyosis–keratoderma (CEDNIK) syndrome, lamellar granule internal structure is normal in ARC syndrome while it is abnormal in CEDNIK syndrome. An additional cause of ichthyosis in ARC syndrome is the lack of absorption of free fatty acids, which are critical for epidermal differentiation [25]. Furthermore, skin biopsy may indicate the presence of mild hyperkeratosis without parakeratosis. Self-limiting intra-abdominal hemorrhage often occurs in patients with ARC, in the absence of abnormal platelet morphology; therefore, normal routine platelet analysis cannot assess the risk of bleeding in ARC syndrome [9]. Despite the increased number of β-granules, similar to Grey platelet syndrome, platelets from patients with ARC syndrome develop abnormal biosynthesis and function of α-granules, which are essential for platelet aggregation, thrombogenesis, inflammation, and tumorigenesis [26],[27]. Studies have demonstrated that a VPS33B-VPS16B complex participates in α-granule formation, since this complex was tracked with transport vesicles destined toward the development of mature α-granules [28],[29]. Moreover, patients with ARC syndrome primarily have recurrent episodes of secondary infection coupled with hyperpyrexia and chronic diarrhea, although their immunological profiles are found to be within normal limits. It has been recently demonstrated that a profound defect in phagosome-lysosome fusion caused by Vps16B/Vps33B dysfunction may render patients with ARC syndrome increasingly sensitive to infections by nonpathogenic microbes [30]. Interestingly, bacterial endocarditis subject to recurrent infection has also been reported to originate from congenital cardiovascular anomalies, other than the structural abnormalities caused by defects in vesicular trafficking [3].

Genetic background

To gain an insight into worldwide genetic epidemiology and provide easy access to updated resources for researchers and clinicians, a Leiden Open-Source Variation Database (LOVD) for ARC ( was established in 2011 by collating all relevant published variants observed in VPS33B and VIPAR[31]. As for March 2014, this online locus-specific ARC database has compiled a total of 299 unique variants in VPS33B and 34 unique variants in VIPAR, of which sequence mutations are basically classified as "pathogenic," "probably pathogenic," "no known pathogenicity," "probably no pathogenicity," and "effect unknown," according to their projected effect on the protein and the clinical phenotype. To date, the database includes 49 published variants in VPS33B and 14 published variants in VIPAR worldwide that have been classified as "pathogenic." Regarding VPS33B, most identified variants were substitutions (n = 34; 19 splice site, 13 nonsense, and two missense mutations), apart from deletions (n = 11), duplications (n = 2), insertions (n = 1), and indels (n = 1). It is noteworthy that three variants were prominent on account of their relative prevalence: c.403 + 2 T > A, c.1312C > T, and c.1519C > T (see Table 2). Most "pathogenic" variants in VIPAR are substitutions (n = 11; 8 nonsense, two missense, and one splice site mutation). Additionally, two deletions were present, of which two recurrent variants existed: c.658C > T and c.808C > T (see Table 3). This information is available in the ARC–LOVD database to inform clinicians and patient families on current prognoses, advances, and clinical course of ARC pathogenesis, ultimately contributing to accurately counseling and improved disease management.

Table 2 Pathogenic VPS33B mutations listed in the ARC-LOVD database
Table 3 Pathogenic VIPAR mutations listed in ARC-LOVD database

Diagnostic clues and workup

In general, case reports of patients with ARC syndrome are not uncommon in Saudi Arabia and Pakistan, where rates of consanguinity are high, whereas several sporadic case studies have been reported in Turkey, North Africa, Italy, Portugal, and Asia [5],[31]-[34]. Despite these reports, the prevalence of ARC syndrome has not been accurately defined and is subject to potential underestimation because of lack of a broad clinical picture and of early recognition of this rare disease. It is worth mentioning that the relative incidence rate ratio of ARC was suggested to be 1/7 that of biliary atresia in 90 patients with neonatal cholestasis (95% CI 0.33 ~ 0.06) [21],[22],[35].

ARC syndrome is a life-threatening autosomal recessive multisystem disorder, and its early diagnosis is of vital importance for the development of an appropriate therapeutic regimen. Currently, clinical diagnosis of ARC syndrome consists of identifying the triad conditions of arthrogryposis, renal tubular acidosis, and neonatal cholestatic jaundice with low γGT activity, combined with pathologic confirmation. However, the majority of patients are vulnerable to coagulation defects; in other words, kidney or liver biopsies result in a risk of fatal bleeding (>50%). Still, similar clinical and laboratory findings could be observed both in ARC syndrome and progressive familial intrahepatic cholestasis. Therefore, clinical presentations along with VPS33B and VIPAR sequencing analyses constitute an apparently safer diagnostic procedure. Currently, there are limitations in mutational analysis, such as the long duration required for analysis and the potential for false negatives, analysis of VPS33B protein expression in skin fibroblasts and platelet morphology in peripheral blood smears are two alternative techniques that have been proposed as valuable tools for diagnostic screening examinations [9],[36].

Treatment options and prognosis

No specific treatment for ARC syndrome currently exists; rather, supportive care—including fluid infusion, anti-infection, supplement with ursodeoxycholic acid, fat-soluble vitamins, calcium glubionate, L-thyroxine and phosphate—is administered to patients for improving the quality of life. Nevertheless, some patients with joint contractures, congenital hip dislocation, and vertical talus are in need of immediate orthopedic intervention due to delayed diagnosis. Nevertheless, aggressive orthopedic management is still not recommended, since poor general status and low survival rates may affect the outcome of the surgery [37]. In cases of ARC syndrome that failed to respond to medical therapy, it is also advisable to consider liver transplant to ameliorate severe cholestasis and intractable pruritus. It is reported that an Iranian boy underwent a liver transplant have made a recovery. Specifically, the pruritus immediately improved after the surgery, and his scaly skin was also normal in 6 months. Moreover, the patient stayed in good condition without any complications or rejection during more than 5 years' follow-up [38].

As a lethal multisystem disorder, prognosis of ARC syndrome is particularly poor. Most patients succumb within the first year of life after developing recurrent infection, severe hydropenia, acidosis, or internal hemorrhaging, except for a few patients who have ARC syndrome but retain partial function of VPS33B[22].


No specific treatment currently exists for ARC syndrome. Comprehensive analysis of family history, classical clinical presentations, biopsy of the liver or kidney, and/or genetic mutational analysis may not only facilitate accurate diagnosis and the development of appropriately tailored treatment at an early stage but also provide genetic counseling and prenatal or preimplantation genetic diagnosis for the affected families. With the continued progress of molecular genetics and medical technologies, future attempts at gene therapy may yield improvements in managing or even curing ARC syndrome.


Written informed consent was obtained from the patient's guardian/parent/next of kin for the publication of this report and any accompanying images.



alanine aminotransferase


Aspartate aminotransferase


ARTHROGRYPOSIS-renal dysfunction-cholestasis


Cerebral dysgenesis–neuropathy–ichthyosis–keratoderma


Class C core vacuole/endosome tethering


Epidermal growth factor


γ-Glutamyl transpeptidase


Homotypic protein sorting


Leiden open-source variation database


Soluble NSF attachment protein receptors

VPS33B :

Vacuolar protein sorting 33 homolog B


VPS33B-interacting protein, apical–basolateral polarity regulator


  1. Lutz-Richner AR, Landolt RF: Familiare Gallengansmissbildungen mit tubularer Neireninsurfizienz. Helv Paediatr Acta. 1973, 28: 1-12.

    Google Scholar 

  2. Taha D, Khider A, Cullinane AR, Gissen P: A novel VPS33B mutation in an ARC syndrome patient presenting with osteopenia and fractures at birth. Am J Med Genet A. 2007, 143A (23): 2835-2837. 10.1002/ajmg.a.32051.

    Article  CAS  PubMed  Google Scholar 

  3. Gissen P, Tee L, Johnson CA, Genin E, Caliebe A, Chitayat D, Clericuzio C, Denecke J, Di Rocco M, Fischler B, FitzPatrick D, Garcia-Cazorla A, Guyot D, Jacquemont S, Koletzko S, Leheup B, Mandel H, Sanseverino MT, Houwen RH, McKiernan PJ, Kelly DA, Maher ER: Clinical and molecular genetic features of ARC syndrome. Hum Genet. 2006, 120 (3): 396-409. 10.1007/s00439-006-0232-z.

    Article  CAS  PubMed  Google Scholar 

  4. Abdullah MA, Al-Hasnan Z, Okamoto E, Abomelha AM: Arthrogryposis, renal dysfunction and cholestasis syndrome. Saudi Med J. 2000, 21 (3): 297-299.

    CAS  PubMed  Google Scholar 

  5. Gissen P, Johnson CA, Morgan NV, Stapelbroek JM, Forshew T, Cooper WN, McKiernan PJ, Klomp LW, Morris AA, Wraith JE, McClean P, Lynch SA, Thompson RJ, Lo B, Quarrell OW, Di Rocco M, Trembath RC, Mandel H, Wali S, Karet FE, Knisely AS, Houwen RH, Kelly DA, Maher ER: Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet. 2004, 36 (4): 400-404. 10.1038/ng1325.

    Article  CAS  PubMed  Google Scholar 

  6. Cullinane AR, Straatman-Iwanowska A, Zaucker A, Wakabayashi Y, Bruce CK, Luo G, Rahman F, Gurakan F, Utine E, Ozkan TB, Denecke J, Vukovic J, Di Rocco M, Mandel H, Cangul H, Matthews RP, Thomas SG, Rappoport JZ, Arias IM, Wolburg H, Knisely AS, Kelly DA, Muller F, Maher ER, Gissen P: Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet. 2010, 42 (4): 303-312. 10.1038/ng.538.

    Article  CAS  PubMed  Google Scholar 

  7. Carim L, Sumoy L, Andreu N, Estivill X, Escarceller M: Cloning, mapping and expression analysis of VPS33B, the human orthologue of rat Vps33b. Cytogenet Cell Genet. 2000, 89 (1-2): 92-95. 10.1159/000015571.

    Article  CAS  PubMed  Google Scholar 

  8. Peterson MR, Emr SD: The class C Vps complex functions at multiple stages of the vacuolar transport pathway. Traffic. 2001, 2 (7): 476-486. 10.1034/j.1600-0854.2001.20705.x.

    Article  CAS  PubMed  Google Scholar 

  9. Cullinane AR, Straatman-Iwanowska A, Seo JK, Ko JS, Song KS, Gizewska M, Gruszfeld D, Gliwicz D, Tuysuz B, Erdemir G, Sougrat R, Wakabayashi Y, Hinds R, Barnicoat A, Mandel H, Chitayat D, Fischler B, Garcia-Cazorla A, Knisely AS, Kelly DA, Maher ER, Gissen P: Molecular investigations to improve diagnostic accuracy in patients with ARC syndrome. Hum Mutat. 2009, 30 (2): E330-E337. 10.1002/humu.20900.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Gissen P, Johnson CA, Gentle D, Hurst LD, Doherty AJ, O'Kane CJ, Kelly DA, Maher ER: Comparative evolutionary analysis of VPS33 homologues: genetic and functional insights. Hum Mol Genet. 2005, 14 (10): 1261-1270. 10.1093/hmg/ddi137.

    Article  CAS  PubMed  Google Scholar 

  11. Zhu GD, Salazar G, Zlatic SA, Fiza B, Doucette MM, Heilman CJ, Levey AI, Faundez V, L'Hernault SW: SPE-39 family proteins interact with the HOPS complex and function in lysosomal delivery. Mol Biol Cell. 2009, 20 (4): 1223-1240. 10.1091/mbc.E08-07-0728.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Tornieri K, Zlatic SA, Mullin AP, Werner E, Harrison R, L'Hernault SW, Faundez V: Vps33b pathogenic mutations preferentially affect VIPAS39/SPE-39-positive endosomes. Hum Mol Genet. 2013, 22 (25): 5215-5228. 10.1093/hmg/ddt378.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Ishii A, Kamimori K, Hiyoshi M, Kido H, Ohta T, Konishi H: Inhibitory effect of SPE-39 due to tyrosine phosphorylation and ubiquitination on the function of Vps33B in the EGF-stimulated cells. Febs Lett. 2012, 586 (16): 2245-2250. 10.1016/j.febslet.2012.05.051.

    Article  CAS  PubMed  Google Scholar 

  14. Zlatic SA, Tornieri K, L'Hernault SW, Faundez V: Metazoan cell biology of the HOPS tethering complex. Cell Logist. 2011, 1 (3): 111-117. 10.4161/cl.1.3.17279.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Matthews RP, Plumb-Rudewiez N, Lorent K, Gissen P, Johnson CA, Lemaigre F, Pack M: Zebrafish vps33b, an ortholog of the gene responsible for human arthrogryposis-renal dysfunction-cholestasis syndrome, regulates biliary development downstream of the onecut transcription factor hnf6. Development. 2005, 132 (23): 5295-5306. 10.1242/dev.02140.

    Article  CAS  PubMed  Google Scholar 

  16. Arhan E, Yusufoglu AM, Sayli TR: Arc syndrome without arthrogryposis, with hip dislocation and renal glomerulocystic appearance: a case report. Eur J Pediatr. 2009, 168 (8): 995-998. 10.1007/s00431-008-0860-5.

    Article  PubMed  Google Scholar 

  17. Bull LN, Mahmoodi V, Baker AJ, Jones R, Strautnieks SS, Thompson RJ, Knisely AS: VPS33B mutation with ichthyosis, cholestasis, and renal dysfunction but without arthrogryposis: incomplete ARC syndrome phenotype. J Pediatr. 2006, 148 (2): 269-271. 10.1016/j.jpeds.2005.10.005.

    Article  CAS  PubMed  Google Scholar 

  18. Sanseverino MT, de Souza CF, Gissen P, Sordi AO, Magalhaes JA, Schuler-Faccini L: Increased nuchal translucency in arthrogryposis, renal dysfunction and cholestasis (ARC) syndrome and discovery of a Portuguese specific mutation in the VPS33B gene. Ultrasound Obstet Gynecol. 2006, 28 (2): 233-234. 10.1002/uog.2822.

    Article  CAS  PubMed  Google Scholar 

  19. Deal JE, Barratt TM, Dillon MJ: Fanconi syndrome, ichthyosis, dysmorphism, jaundice and diarrhoea–a new syndrome. Pediatr Nephrol. 1990, 4 (4): 308-313. 10.1007/BF00862505.

    Article  CAS  PubMed  Google Scholar 

  20. Malaki M, Mandana R, Ghaffari S: ARC syndrome with complex renal problems: nephrocalcinosis, proximal and hyperkalemic distal RTA and nephrogenic diabetes insipidus. Saudi J Kidney Dis Transpl. 2012, 23 (4): 804-809. 10.4103/1319-2442.98165.

    Article  PubMed  Google Scholar 

  21. Jang JY, Kim KM, Kim GH, Yu E, Lee JJ, Park YS, Yoo HW: Clinical characteristics and VPS33B mutations in patients with ARC syndrome. J Pediatr Gastroenterol Nutr. 2009, 48 (3): 348-354. 10.1097/MPG.0b013e31817fcb3f.

    Article  PubMed  Google Scholar 

  22. Eastham KM, McKiernan PJ, Milford DV, Ramani P, Wyllie J, Van'T HW, Lynch SA, Morris AA: ARC syndrome: an expanding range of phenotypes. Arch Dis Child. 2001, 85 (5): 415-420. 10.1136/adc.85.5.415.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Choi HJ, Lee MW, Choi JH, Moon KC, Koh JK: Ichthyosis associated with ARC syndrome: ARC syndrome is one of the differential diagnoses of ichthyosis. Pediatr Dermatol. 2005, 22 (6): 539-542. 10.1111/j.1525-1470.2005.00135.x.

    Article  PubMed  Google Scholar 

  24. Franceschini P, Barberis L: Arthrogryposis, renal tubular dysfunction, cholestasis, ichthyosis syndrome (ARCI). Eur J Pediatr. 1997, 156 (1): 78-

    CAS  PubMed  Google Scholar 

  25. Hershkovitz D, Mandel H, Ishida-Yamamoto A, Chefetz I, Hino B, Luder A, Indelman M, Bergman R, Sprecher E: Defective lamellar granule secretion in arthrogryposis, renal dysfunction, and cholestasis syndrome caused by a mutation in VPS33B. Arch Dermatol. 2008, 144 (3): 334-340.

    Article  CAS  PubMed  Google Scholar 

  26. Flaumenhaft R: Alpha-granules: a story in the making. Blood. 2012, 120 (25): 4908-4909. 10.1182/blood-2012-10-459115.

    Article  CAS  PubMed  Google Scholar 

  27. Saadah OI, Bokhari BE, Alshaeri TM, Jastaniah W: Haematological manifestations of arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome: a case report. Arab J Gastroenterol. 2013, 14 (1): 26-28. 10.1016/j.ajg.2013.01.001.

    Article  PubMed  Google Scholar 

  28. Lo B, Li L, Gissen P, Christensen H, McKiernan PJ, Ye C, Abdelhaleem M, Hayes JA, Williams MD, Chitayat D, Kahr WH: Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood. 2005, 106 (13): 4159-4166. 10.1182/blood-2005-04-1356.

    Article  CAS  PubMed  Google Scholar 

  29. Urban D, Li L, Christensen H, Pluthero FG, Chen SZ, Puhacz M, Garg PM, Lanka KK, Cummings JJ, Kramer H, Wasmuth JD, Parkinson J, Kahr WH: The VPS33B-binding protein VPS16B is required in megakaryocyte and platelet alpha-granule biogenesis. Blood. 2012, 120 (25): 5032-5040. 10.1182/blood-2012-05-431205.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Akbar MA, Tracy C, Kahr WH, Kramer H: The full-of-bacteria gene is required for phagosome maturation during immune defense in Drosophila. J Cell Biol. 2011, 192 (3): 383-390. 10.1083/jcb.201008119.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Smith H, Galmes R, Gogolina E, Straatman-Iwanowska A, Reay K, Banushi B, Bruce CK, Cullinane AR, Romero R, Chang R, Ackermann O, Baumann C, Cangul H, Cakmak CF, Aygun C, Coward R, Dionisi-Vici C, Sibbles B, Inward C, Kim CA, Klumperman J, Knisely AS, Watson SP, Gissen P: Associations among genotype, clinical phenotype, and intracellular localization of trafficking proteins in ARC syndrome. Hum Mutat. 2012, 33 (12): 1656-1664. 10.1002/humu.22155.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Li LT, Zhao J, Chen R, Wang JS: Two novel VPS33B mutations in a patient with arthrogryposis, renal dysfunction and cholestasis syndrome in mainland China. World J Gastroenterol. 2014, 20 (1): 326-329. 10.3748/wjg.v20.i1.326.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Kim KM, Kim GH, Park YS, Yoo HW: Aberrant splicing by a mutation, c.403 + 2 T > A, in Korean patients with arthrogryposis-renal-dysfunction-cholestasis syndrome. Pediatr Int. 2011, 53 (4): 609-610. 10.1111/j.1442-200X.2011.03418.x.

    Article  CAS  PubMed  Google Scholar 

  34. Tekin N, Durmus-Aydogdu S, Dinleyici EC, Bor O, Bildirici K, Aksit A: Clinical and pathological aspects of ARC (arthrogryposis, renal dysfunction and cholestasis) syndrome in two siblings. Turk J Pediatr. 2005, 47 (1): 67-70.

    PubMed  Google Scholar 

  35. Abu-Sa'Da O, Barbar M, Al-Harbi N, Taha D: Arthrogryposis, renal tubular acidosis and cholestasis (ARC) syndrome: two new cases and review. Clin Dysmorphol. 2005, 14 (4): 191-196. 10.1097/00019605-200510000-00005.

    Article  PubMed  Google Scholar 

  36. Kim SM, Chang HK, Song JW, Koh H, Han SJ: Agranular platelets as a cardinal feature of ARC syndrome. J Pediatr Hematol Oncol. 2010, 32 (4): 253-258. 10.1097/MPH.0b013e3181c3a8d0.

    Article  PubMed  Google Scholar 

  37. Jang WY, Cho TJ, Bae JY, Jung HW, Ko JS, Park MS, Yoo WJ, Chung CY, Seo JK, Choi IH: Orthopaedic manifestations of arthrogryposis-renal dysfunction-cholestasis syndrome. J Pediatr Orthop. 2011, 31 (1): 107-112. 10.1097/BPO.0b013e3182032c83.

    Article  PubMed  Google Scholar 

  38. Dehghani SM, Bahador A, Nikeghbalian S, Salahi H, Geramizadeh B, Malekpour A, Malek-Hosseini SA: Liver transplant in a case of arthrogryposis-renal tubular dysfunction-cholestasis syndrome with severe intractable pruritus. Exp Clin Transplant. 2013, 11 (3): 290-292. 10.6002/ect.2012.0202.

    Article  PubMed  Google Scholar 

Download references


We gratefully acknowledge the project supported by No. 3 People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine (syz2013-001, to Dr. Zhang).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Junfeng Zhang.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

YZ participated in the design and draft of the manuscript. JZ was involved in designing and revising the manuscript critically for important intellectual content. Both authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., Zhang, J. Arthrogryposis–renal dysfunction–cholestasis (ARC) syndrome: from molecular genetics to clinical features. Ital J Pediatr 40, 77 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: